Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine kinases inhibitors – dasatinib and nilotinib – is...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/30 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241193421996032 |
|---|---|
| author | E. G. Lomaia E. G. Romanova E. I. Sbityakova A. Yu. Zaritskiy |
| author_facet | E. G. Lomaia E. G. Romanova E. I. Sbityakova A. Yu. Zaritskiy |
| author_sort | E. G. Lomaia |
| collection | DOAJ |
| description | Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine kinases inhibitors – dasatinib and nilotinib – is also possible. The article represents a literature review evaluating efficacy and toxicity of both drugs and highlighting some of the practical issues of CML treatment after first-line therapy failure. |
| format | Article |
| id | doaj-art-bd6366f52ce34cf9921f1414a935f0ff |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-bd6366f52ce34cf9921f1414a935f0ff2025-08-20T04:00:14ZrusABV-pressОнкогематология1818-83462413-40232014-07-0182223310.17650/1818-8346-2013-8-2-22-3345Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemiaE. G. Lomaia0E. G. Romanova1E. I. Sbityakova2A. Yu. Zaritskiy3Almazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of RussiaAlmazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of RussiaAlmazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of Russia Saint Petersburg Pavlov State Medical University, Ministry of Health of RussiaAlmazov Federal Heart, Blood and Endocrinology Center, Ministry of Health of Russia Saint Petersburg Pavlov State Medical University, Ministry of Health of RussiaCurrent treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine kinases inhibitors – dasatinib and nilotinib – is also possible. The article represents a literature review evaluating efficacy and toxicity of both drugs and highlighting some of the practical issues of CML treatment after first-line therapy failure.https://oncohematology.abvpress.ru/ongm/article/view/30chronic myeloid leukemiadasatinibnilotinib |
| spellingShingle | E. G. Lomaia E. G. Romanova E. I. Sbityakova A. Yu. Zaritskiy Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia Онкогематология chronic myeloid leukemia dasatinib nilotinib |
| title | Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia |
| title_full | Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia |
| title_fullStr | Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia |
| title_full_unstemmed | Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia |
| title_short | Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia |
| title_sort | efficacy and safety of tyrosine kinase inhibitors dasatinib nilotinib in the treatment of chronic phase chronic myeloid leukemia |
| topic | chronic myeloid leukemia dasatinib nilotinib |
| url | https://oncohematology.abvpress.ru/ongm/article/view/30 |
| work_keys_str_mv | AT eglomaia efficacyandsafetyoftyrosinekinaseinhibitorsdasatinibnilotinibinthetreatmentofchronicphasechronicmyeloidleukemia AT egromanova efficacyandsafetyoftyrosinekinaseinhibitorsdasatinibnilotinibinthetreatmentofchronicphasechronicmyeloidleukemia AT eisbityakova efficacyandsafetyoftyrosinekinaseinhibitorsdasatinibnilotinibinthetreatmentofchronicphasechronicmyeloidleukemia AT ayuzaritskiy efficacyandsafetyoftyrosinekinaseinhibitorsdasatinibnilotinibinthetreatmentofchronicphasechronicmyeloidleukemia |